Total submissions: 9
Submitter | RCV | SCV | Clinical significance | Condition | Last evaluated | Review status | Method | Comment |
---|---|---|---|---|---|---|---|---|
Lupski Lab, |
RCV000488909 | SCV000267601 | likely pathogenic | not provided | 2016-04-26 | criteria provided, single submitter | research | recurrent de novo variant identified in 5 probands |
Rady Children's Institute for Genomic Medicine, |
RCV000412539 | SCV000996108 | pathogenic | Harel-Yoon syndrome | 2018-02-08 | criteria provided, single submitter | clinical testing | This variant has been previously reported as a de novo change in multiple unrelated individuals with developmental delay and additional features (PMID: 27640307). An analysis of fibroblasts derived from an affected individual with this variant and the features of Harel-Yoon syndrome showed increased mitochondrial degradation (PMID: 27640307). Similarly, a reduction in mitochondrial content and aberrant mitochondrial morphology were observed in Drosophila harboring this mutation (PMID: 27640307). This variant is absent from the ExAC and gnomAD population databases. Algorithms developed to predict the effect of missense changes on protein function suggest this variant is likely to be deleterious. Analysis of the parental samples was negative for the variant, indicating this variant likely occurred as a de novo event. Based on the available evidence, the p.Arg576Trp variant in ATAD3A is classified as pathogenic change. |
Genomics England Pilot Project, |
RCV000412539 | SCV001759978 | pathogenic | Harel-Yoon syndrome | criteria provided, single submitter | clinical testing | ||
Gene |
RCV000488909 | SCV001823919 | pathogenic | not provided | 2022-02-17 | criteria provided, single submitter | clinical testing | Published functional studies demonstrate a damaging effect including reduction in mitochondria density and number in motor neurons and muscle, as well as an increase in mitophagic vesicles (Harel et al., 2016); Not observed at significant frequency in large population cohorts (gnomAD); In silico analysis, which includes protein predictors and evolutionary conservation, supports a deleterious effect; This variant is associated with the following publications: (PMID: 33146414, 27640307, 28327206, 31019026) |
Provincial Medical Genetics Program of British Columbia, |
RCV000412539 | SCV002320855 | pathogenic | Harel-Yoon syndrome | 2022-01-01 | criteria provided, single submitter | clinical testing | |
3billion, |
RCV000412539 | SCV002521182 | pathogenic | Harel-Yoon syndrome | 2022-05-22 | criteria provided, single submitter | clinical testing | The variant is not observed in the gnomAD v2.1.1 dataset. Functional studies provide strong evidence of the variant having a damaging effect on the gene or gene product (PMID:27640307). In silico tool predictions suggest damaging effect of the variant on gene or gene product (REVEL: 0.72; 3Cnet: 0.85). Same nucleotide change resulting in same amino acid change has been previously reported as pathogenic/likely pathogenic with strong evidence (ClinVar ID: VCV000225696). The variant has been previously reported as de novo in at least two similarly affected unrelated individuals (PMID: 27640307). Therefore, this variant is classified as pathogenic according to the recommendation of ACMG/AMP guideline. |
OMIM | RCV000412539 | SCV000490326 | pathogenic | Harel-Yoon syndrome | 2020-03-23 | no assertion criteria provided | literature only | |
Lupski Lab, |
RCV000412539 | SCV000494159 | pathogenic | Harel-Yoon syndrome | flagged submission | research | This variant has been identified as de novo in 5 individuals with delayed motor development and hypotonia. Please see PMID: 27640307 for full description. | |
University of Washington Center for Mendelian Genomics, |
RCV000412539 | SCV000993446 | pathogenic | Harel-Yoon syndrome | 2017-05-25 | no assertion criteria provided | research |